ECTRIMS: European Committee for Treatment and Research in Multiple Sclerosis
Conference Coverage
MS-related disability may be decreasing
STOCKHOLM – International data indicate that the prognosis of MS has improved, partly as a result of treatment.
Conference Coverage
Adolescent lung inflammation may trigger later MS
STOCKHOLM – Swedish national health care registry studies show associations between pneumonia or infectious mononucleosis occurring in early...
Conference Coverage
Smoking impairs cognition and shrinks brain volume in MS
STOCKHOLM – New evidence suggests the damage may be partially reversible.
Conference Coverage
In patients with CIS, combined omics predicts conversion to clinically definite MS
STOCKHOLM – Oligoclonal band status is helpful for diagnosis, but cannot predict who will go on to develop clinically definite MS.
Conference Coverage
Investigators use ARMSS score to predict future MS-related disability
STOCKHOLM – The score is the basis for a measurement that is stable over time.
Conference Coverage
Intensive cognitive training may be needed for memory gains in MS
STOCKHOLM – Patients with MS saw the best results with the most intensive memory strategies.
Conference Coverage
Baseline neurofilament light levels track with brain volume loss in MS
STOCKHOLM – Ten-year data strengthen neurofilament light’s potential prognostic role.
Conference Coverage
Tocilizumab beat azathioprine for NMOSD
STOCKHOLM – The first-ever head-to-head trial compared the two drugs in highly relapsing neuromyelitis optica spectrum disorder.
Conference Coverage
Cannabis-using MS patients improve cognition with 28 days of abstinence
STOCKHOLM – “It’s good for neurologists to know that, if they prescribe cannabis or their patient is self-medicating and chooses to stop, their...
Conference Coverage
Continuation of natalizumab treatment reduces risk of MS relapses during pregnancy
STOCKHOLM – Natalizumab treatment after the first trimester may not be associated with significant fetal risks.
Conference Coverage
Even with no disease activity, recurrence risk near 50% when stopping DMTs for MS
STOCKHOLM – Younger patients had a significantly higher risk of recurrence when stopping disease modifying therapy.
Conference Coverage
Plasma exchange in natalizumab-related PML shows no benefit, possible harm
STOCKHOLM – Biggest-ever study of natalizumab-associated PML in patients with multiple sclerosis raises red flag regarding common practice of...
Conference Coverage
Ofatumumab has superior efficacy in relapsing-remitting MS, compared with teriflunomide
STOCKHOLM – The monoclonal antibody reduced annualized relapse rate and the risk of confirmed disability worsening,...
Conference Coverage
Newer drugs provide superior disease activity control in pediatric MS
STOCKHOLM – Study from U.S. Network of Pediatric MS Centers supports early use of newer disease-modifying therapies.
Conference Coverage
Inebilizumab looks good for neuromyelitis optica in phase 2/3 trial
STOCKHOLM – Attacks were significantly reduced and a marker for tissue damage dropped, but IgG levels will likely have to be tracked long term.